Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow VivoSim Labs, INC.

Get SEC filing alerts via email and in your feed for VivoSim Labs, INC.

VIVS

VivoSim Labs, INC.

About VivoSim Labs, INC.

VivoSim Labs, Inc. specializes in providing testing services using 3D human tissue models of liver and intestine for drug safety and toxicology assessment. The company develops and offers bespoke toxicology insights, supporting pharmaceutical and biotech clients throughout drug development. Leveraging proprietary bioprinting and tissue engineering technologies, VivoSim aims to reduce drug development risks and costs, with a focus on non-animal testing methodologies and advanced disease models.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from VivoSim Labs, INC.

1
1
VivoSim Labs, INC. VivoSim Labs Reports Q3 Revenue Increase and Strategic Shift to Toxicology Services

Via official filing (AI summary) | 4 months ago | 0 comments

2
1
VivoSim Labs, INC. VivoSim Labs Reports Q2 Fiscal 2026 Revenue Decline and Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

3
1
VivoSim Labs, INC. VivoSim Labs Reports Revenue Increase and Reduced Net Loss for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

4
1
VivoSim Labs, INC. VivoSim Labs Reports Shift in Business Model and Financial Performance for Fiscal Year Ending March 31, 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

5
1
VivoSim Labs, INC. Organovo Reports Revenue Growth to $24,000 but Faces Net Loss and Financial Challenges

Via official filing (AI summary) | over 1 year ago | 0 comments

6
1
VivoSim Labs, INC. Organovo Holdings Reports Improved Financials, Advances FXR314 Development for Inflammatory Bowel Disease

Via official filing (AI summary) | over 1 year ago | 0 comments